As of close of business last night, Esperion Therapeutics Inc.’s stock clocked out at $2.44, down -4.31% from its previous closing price of $2.55. In other words, the price has decreased by -$0.1100 from its previous closing price. On the day, 3227596 shares were traded.
Ratios:
To gain a deeper understanding of ESPR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.29.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 20 when Warren Eric sold 742 shares for $1.25 per share. The transaction valued at 924 led to the insider holds 68,318 shares of the business.
Warren Eric sold 243 shares of ESPR for $344 on Aug 18. The Chief Commercial Officer now owns 69,060 shares after completing the transaction at $1.41 per share. On Jul 19, another insider, Warren Eric, who serves as the Chief Commercial Officer of the company, sold 106 shares for $1.58 each. As a result, the insider received 168 and left with 69,303 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 472.81M and an Enterprise Value of 656.73M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.57. Its current Enterprise Value per Revenue stands at 5.65 whereas that against EBITDA is -4.38.
Stock Price History:
Over the past 52 weeks, ESPR has reached a high of $6.74, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is 2.5084, while the 200-Day Moving Average is calculated to be 1.6171.
Shares Statistics:
It appears that ESPR traded 6.38M shares on average per day over the past three months and 4.86M shares per day over the past ten days. A total of 170.42M shares are outstanding, with a floating share count of 169.51M. Insiders hold about 0.53% of the company’s shares, while institutions hold 48.10% stake in the company. Shares short for ESPR as of Feb 15, 2024 were 18.57M with a Short Ratio of 2.91, compared to 20.2M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.03% and a Short% of Float of 11.21%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0.46 and a low estimate of -$0.36, while EPS last year was -$0.79. The consensus estimate for the next quarter is -$0.04, with high estimates of $0.94 and low estimates of -$0.25.
Analysts are recommending an EPS of between $2.5 and -$1 for the fiscal current year, implying an average EPS of $0.02. EPS for the following year is $0.2, with 6 analysts recommending between $1.49 and -$0.34.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $84.63M. It ranges from a high estimate of $141.69M to a low estimate of $28.9M. As of the current estimate, Esperion Therapeutics Inc.’s year-ago sales were $24.33M, an estimated increase of 247.90% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $41.91M, an increase of 62.50% less than the figure of $247.90% in the same quarter last year. There is a high estimate of $48.35M for the next quarter, whereas the lowest estimate is $38M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $649.2M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $313.61M. In the same quarter a year ago, actual revenue was $116.33M, up 169.60% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $401.72M in the next fiscal year. The high estimate is $710.2M and the low estimate is $272.94M. The average revenue growth estimate for next year is up 28.10% from the average revenue estimate for this year.
